Michael Grey Biography and Net Worth

Chairman of the Board of Mirum Pharmaceuticals

Mike Grey has served as chairman of the board since January 2020. Previously he served as executive chairman since March 2019. Mike is a co-founder of Mirum.

Mike previously served as chief executive officer from the company’s inception in May 2018 to March 2019. Mr. Grey has served as executive chairman of Plexium, Inc. since January 2021; Reneo Pharmaceuticals, Inc. since December 2017; and Spruce Biosciences, Inc, since April 2017. He has also served as a venture partner at Pappas Ventures since January 2010 and as president and chief executive officer of Curzion Pharmaceuticals, Inc. Mike served from October 2015 to January 2017 as the president and chief executive officer of Amplyx and from September 2014 to December 2017 as chairman and chief executive officer of Reneo. From February 2011 to June 2014, Mike served as president and chief executive officer of Lumena, which was acquired by Shire plc in June 2014. Mike has 40 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and president of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as vice president, corporate development and director of international licensing. Mr. Grey also serves on the board of directors of Horizon Therapeutics plc.

Mike received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

What is Michael G. Grey's net worth?: The estimated net worth of Michael G. Grey is at least $694,200.00 as of April 12th, 2021. Mr. Grey owns 15,000 shares of Mirum Pharmaceuticals stock worth more than $694,200 as of March 27th. This net worth evaluation does not reflect any other investments that Mr. Grey may own. Learn More about Michael G. Grey's net worth.
How do I contact Michael G. Grey?: The corporate mailing address for Mr. Grey and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Michael G. Grey's contact information.
Has Michael G. Grey been buying or selling shares of Mirum Pharmaceuticals?: Michael G. Grey has not been actively trading shares of Mirum Pharmaceuticals during the last quarter. Learn More on Michael G. Grey's trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Michael G. Grey Insider Trading History at Mirum Pharmaceuticals

Michael G. Grey Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $46.28

$45.83

$47.20

50 Day Range

MA: $48.02

$43.01

$53.16

2 Week Range

Now: $46.28

$23.14

$54.23

Volume

393,047 shs

Average Volume

509,454 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04